Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Glenmark Pharmaceuticals Ltd.

Latest From Glenmark Pharmaceuticals Ltd.

Pipeline Watch: Phase II Readouts With SPK-8011, Velusetrag, GBR-830

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Approvals Pipeline Watch

India’s New GST Tax A Game Changer For Pharma But Challenges Ahead

India’s ambitious new Goods and Services Tax, aimed at turning the country into a single common market, will be a ‘game-changer’ with a mix of impacts for the pharma industry and the rest of the economy, but the rollout involves overcoming considerable logistical challenges.

Commercial Companies

Deal Watch: Merck KGAA, Pfizer, eFFECTOR Agree To PD-L1/MNK Combo Study In CRC

Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.

Deals M & A

Glenmark Shapes Immuno-Oncology Play With Early-Stage APC Asset

Glenmark Pharmaceuticals has in-licensed a small molecule oncology compound from APC Therapeutics Inc, expanding its interests in the promising immuno-oncology space. One of the founders of APC has even joined the Indian firm.

Research & Development Cancer
See All

Company Information